For instance, Siltuximab, an IL-6 antagonist, has demonstrated favourable tolerability in clinical trials but has not shown significant survival benefits in patients with prostate cancer [69], clear cell renal cancer [70], or other solid tumours such as ovarian cancer [71]. Here, IL6 is linked to prostate carcinoma.